MSB 0.51% 97.0¢ mesoblast limited

MSB Trading - 2020, page-6876

  1. 7,825 Posts.
    lightbulb Created with Sketch. 1344
    Also, again why it's important to exercise caution, a small randomised control trial of remdesmivir in China just showed the improvements were not clinically significant.

    Larger trials need to be done. And these trials were using much larger numbers than the remestemcell data that drove this SP through the roof, and we still don't know if remdesmivir is useful.

    Who knows what will come of this. Exciting times.

    Be careful and DYOR
  2. This thread is closed.

    You may not reply to this discussion at this time.

 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.